Paradigm Biopharmaceuticals Limited

FRC's fair value estimate for Paradigm Biopharmaceuticals Limited, and the rating behind it. PAR.AX last traded at AUD 0.17; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Valuation, profitability, liquidity and leverage ratios for Paradigm Biopharmaceuticals Limited. Starting points for Paradigm Biopharmaceuticals Limited: EPS -AUD 0.16, beta -0.01 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend history, yield and payout sustainability for Paradigm Biopharmaceuticals Limited. Paradigm Biopharmaceuticals Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Reported vs. expected earnings history for Paradigm Biopharmaceuticals Limited. Trailing twelve-month EPS for Paradigm Biopharmaceuticals Limited stands at -AUD 0.16. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Income statement, balance sheet and cash flow history for Paradigm Biopharmaceuticals Limited. Paradigm Biopharmaceuticals Limited has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Paradigm Biopharmaceuticals Limited valued side by side against its closest peers. Paradigm Biopharmaceuticals Limited is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Which institutions hold Paradigm Biopharmaceuticals Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Buying and selling by Paradigm Biopharmaceuticals Limited executives and directors. Shares of Paradigm Biopharmaceuticals Limited have traded between AUD 0.14 and AUD 0.47 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

U.S. Senate disclosures naming Paradigm Biopharmaceuticals Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

U.S. House of Representatives disclosures naming Paradigm Biopharmaceuticals Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

Latest headlines and company announcements for Paradigm Biopharmaceuticals Limited. Coverage tracks Paradigm Biopharmaceuticals Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.